Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 4 | Biomarker Research

Fig. 4

From: Roles of IFN-γ in tumor progression and regression: a review

Fig. 4

Interferon-γ contributes to cancer immunotherapy efficacy. The efficacy of anti-PD-1-antibody and anti-CTLA4-antibody in cancer treatment may be improved or diminished by the presence of IFN-γ. Tumor progression: The downregulation of IFN-γ/IFNGR pathway may decrease the efficacy of cancer immunotherapy. The IFN-γ drive expression of inhibitory ligands (IDILs) on tumor cells such as TNFRSF14, LGALS9, MHCII, CD86, IFIT1 and MX1 to dampen the immune response. Moreover, IFN-γ exerts apoptotic effects on immune effector tumor-infiltrating cells. Tumor regression: Increased expression of interferon signature genes (IFNG, CD274, LAG3, and CXCL9) or IFN-γ concentration in the TME is linked to better ICB efficacy. IFNGR-interferon gamma receptor; IDILs-interferon-driven inhibitory ligands; TILs-tumor infiltrating lymphocytes; ISGs-interferon signature genes; ICB-immune checkpoint blockade; TME-tumor microenvironment

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us